ES2628075T3 - Molécula de anticuerpo biespecífica - Google Patents
Molécula de anticuerpo biespecífica Download PDFInfo
- Publication number
- ES2628075T3 ES2628075T3 ES12798623.0T ES12798623T ES2628075T3 ES 2628075 T3 ES2628075 T3 ES 2628075T3 ES 12798623 T ES12798623 T ES 12798623T ES 2628075 T3 ES2628075 T3 ES 2628075T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- domain
- cells
- cell
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000027455 binding Effects 0.000 abstract description 49
- 239000000427 antigen Substances 0.000 abstract description 27
- 108091007433 antigens Proteins 0.000 abstract description 27
- 102000036639 antigens Human genes 0.000 abstract description 27
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 20
- 102000018358 immunoglobulin Human genes 0.000 abstract description 20
- 108010087819 Fc receptors Proteins 0.000 abstract description 19
- 102000009109 Fc receptors Human genes 0.000 abstract description 19
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract description 11
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract description 11
- 125000000539 amino acid group Chemical group 0.000 abstract description 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 abstract description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 75
- 108090000623 proteins and genes Proteins 0.000 description 28
- 239000012634 fragment Substances 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 239000012636 effector Substances 0.000 description 16
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 15
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 10
- 108091008874 T cell receptors Proteins 0.000 description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- -1 ILR-1 Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 230000001461 cytolytic effect Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 7
- 108060006698 EGF receptor Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 6
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 6
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 6
- 229940127174 UCHT1 Drugs 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 5
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108700012439 CA9 Proteins 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 4
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 102000006240 membrane receptors Human genes 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010058905 CD44v6 antigen Proteins 0.000 description 3
- 101150029707 ERBB2 gene Proteins 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 3
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 3
- 101710160107 Outer membrane protein A Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 102000007000 Tenascin Human genes 0.000 description 3
- 108010008125 Tenascin Proteins 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 2
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 102100030438 Derlin-1 Human genes 0.000 description 2
- 101710178882 Derlin-1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 2
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 2
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101100396742 Homo sapiens IL3RA gene Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101150056647 TNFRSF4 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000722921 Tulipa gesneriana Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056549 human Fv Human genes 0.000 description 1
- 108700005872 human Fv Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000052185 transforming growth factor beta receptor activity proteins Human genes 0.000 description 1
- 108700015056 transforming growth factor beta receptor activity proteins Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161577327P | 2011-12-19 | 2011-12-19 | |
| US201161577327P | 2011-12-19 | ||
| PCT/EP2012/072364 WO2013092001A1 (en) | 2011-12-19 | 2012-11-12 | Bispecific antibody molecule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2628075T3 true ES2628075T3 (es) | 2017-08-01 |
Family
ID=47326063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12798623.0T Active ES2628075T3 (es) | 2011-12-19 | 2012-11-12 | Molécula de anticuerpo biespecífica |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9718893B2 (enExample) |
| EP (1) | EP2794658B1 (enExample) |
| JP (1) | JP6441079B2 (enExample) |
| CN (1) | CN104203981A (enExample) |
| BR (1) | BR112014015018A2 (enExample) |
| CA (1) | CA2859767C (enExample) |
| DK (1) | DK2794658T3 (enExample) |
| EA (1) | EA201400709A1 (enExample) |
| ES (1) | ES2628075T3 (enExample) |
| HR (1) | HRP20170658T1 (enExample) |
| HU (1) | HUE033245T2 (enExample) |
| LT (1) | LT2794658T (enExample) |
| SI (1) | SI2794658T1 (enExample) |
| WO (1) | WO2013092001A1 (enExample) |
Families Citing this family (170)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| EP2647707B1 (en) | 2010-11-30 | 2018-09-12 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
| CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
| RU2632647C2 (ru) | 2011-04-22 | 2017-10-06 | Аптево Рисерч Энд Девелопмент Ллс | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| DK2794658T3 (en) * | 2011-12-19 | 2017-06-19 | Synimmune Gmbh | BISPECIFIC ANTIBODY MOLECULE |
| WO2014076292A1 (en) * | 2012-11-19 | 2014-05-22 | Baliopharm Ag | Recombinant bispecific antibody binding to cd20 and cd95 |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| HRP20251426T1 (hr) | 2013-05-06 | 2026-01-02 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| EP4067383A1 (en) | 2013-07-25 | 2022-10-05 | Cytomx Therapeutics Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| RU2016115866A (ru) * | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
| KR20230004939A (ko) * | 2014-02-07 | 2023-01-06 | 맥마스터 유니버시티 | 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도 |
| CN106062193B (zh) * | 2014-02-28 | 2020-08-25 | 安斯泰来制药株式会社 | 与人tlr2及人tlr4结合的双特异性抗体 |
| EP3725812B1 (en) * | 2014-03-03 | 2023-09-27 | Academia Sinica | Bi-specific antibodies and uses thereof |
| US11485790B2 (en) | 2014-04-07 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| CA2952727A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific nkp46 binding proteins |
| PE20170286A1 (es) | 2014-07-01 | 2017-03-30 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos |
| CN104558192B (zh) * | 2015-01-21 | 2018-12-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体her2xcd3的构建及应用 |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| US10556964B2 (en) * | 2014-07-21 | 2020-02-11 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| AU2015305531B2 (en) | 2014-08-19 | 2021-05-20 | Novartis Ag | Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment |
| EP3191526B1 (en) | 2014-09-12 | 2023-02-22 | The Board of Trustees of the Leland Stanford Junior University | Wnt signaling agonist molecules |
| WO2016077638A1 (en) * | 2014-11-12 | 2016-05-19 | Memorial Sloan Kettering Cancer Center | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| IL278574B2 (en) | 2014-11-12 | 2024-11-01 | Seagen Inc | Glycan-interacting compounds and methods of use |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| HRP20250129T1 (hr) | 2014-12-15 | 2025-04-11 | The Regents Of The University Of California | Bispecifični or-gate kimerni antigenski receptor koji reagira na cd19 i cd20 |
| EP3237005B1 (en) * | 2014-12-22 | 2024-09-18 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| CN105821029A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
| CN104774268B (zh) * | 2015-01-21 | 2018-09-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体egfr×cd3的构建及应用 |
| CN104558193B (zh) * | 2015-01-21 | 2019-01-11 | 武汉友芝友生物制药有限公司 | 一种靶向鼠t淋巴细胞cd3和人肿瘤抗原her2的双特异性抗体制备方法及应用 |
| CN104628866B (zh) * | 2015-01-21 | 2018-03-27 | 中国药科大学 | 一种靶向vegfr2的抗体融合蛋白的制备及其用途 |
| CN104592391B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| CN104788567B (zh) * | 2015-01-21 | 2019-03-26 | 武汉友芝友生物制药有限公司 | 一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用 |
| CN104592395B (zh) * | 2015-01-27 | 2017-11-14 | 中国药科大学 | Vegfr2单链抗体与mica融合蛋白的制备方法及用途 |
| WO2016207867A1 (en) | 2015-02-25 | 2016-12-29 | Université Du Luxembourg | Nat8l and n-acetylaspartate in cancer |
| EP3064507A1 (en) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| WO2016178996A1 (en) | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
| CN115109158A (zh) | 2015-05-07 | 2022-09-27 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
| US20180194861A1 (en) * | 2015-07-10 | 2018-07-12 | Abbvie Inc. | IgM- or IgE-Modified Binding Proteins and Uses Thereof |
| TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| CN107106682B (zh) | 2015-08-26 | 2021-05-25 | 比森医疗股份有限公司 | 多特异性抗体平台和相关方法 |
| LU92815B1 (en) | 2015-09-04 | 2017-03-20 | Univ Luxembourg | Inhibitor of dj-1 for therapy |
| CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| WO2017055398A2 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory tnf receptor |
| CR20180171A (es) * | 2015-10-07 | 2018-05-03 | Hoffmann La Roche | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador |
| WO2017066136A2 (en) * | 2015-10-13 | 2017-04-20 | Eureka Therapeutics, Inc. | Antibody agents specific for human cd19 and uses thereof |
| BR112018009004A8 (pt) | 2015-11-03 | 2019-02-26 | Ambrx Inc | conjugados anti-cd3-folato e seus usos |
| EP3373969A4 (en) | 2015-11-12 | 2019-08-14 | Siamab Therapeutics, Inc. | GLYCANINTERAGING COMPOUNDS AND METHOD OF USE |
| EP3374389A1 (en) * | 2015-11-13 | 2018-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| EP3192810A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
| CN114716557A (zh) | 2016-02-03 | 2022-07-08 | 安进研发（慕尼黑）股份有限公司 | Psma和cd3双特异性t细胞接合抗体构建体 |
| WO2017158339A1 (en) * | 2016-03-15 | 2017-09-21 | Cancer Research Technology Limited | Antibodies and related molecules and uses thereof |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| US11104738B2 (en) | 2016-04-04 | 2021-08-31 | Hemogenyx Pharmaceuticals Llc | Monoclonal antibodies to human FLT3/FLK2 receptor protein |
| EP3439699A4 (en) | 2016-04-04 | 2019-11-20 | Hemogenyx LLC | METHOD FOR ELIMINATING HEMATOPOETIC STEM CELLS / HEMATOPOIDIC PRECURSOR CELLS (HSC / HP) IN A PATIENT WITH BI-SPECIFIC ANTIBODIES |
| EP4050032A1 (en) | 2016-06-28 | 2022-08-31 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| GB201611530D0 (en) * | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| CN106632681B (zh) | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| WO2018071913A2 (en) * | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| JP7350313B2 (ja) | 2016-12-16 | 2023-09-26 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 |
| BR112019013189A2 (pt) | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa |
| CA3053010A1 (en) * | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| BR112019018043A2 (pt) | 2017-03-03 | 2020-04-07 | Seattle Genetics Inc | método de tratamento de câncer, e, conjugado de anticorpo-fármaco |
| CN113603780B (zh) * | 2017-03-28 | 2022-07-01 | 礼进生物医药科技（上海）有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
| EP3601345A1 (en) * | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| CN110382542B (zh) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
| JP7381345B2 (ja) * | 2017-05-16 | 2023-11-15 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｍａｎａボディおよび使用方法 |
| CN108948195B (zh) * | 2017-05-23 | 2022-05-31 | 胡毅 | 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途 |
| CA3064714A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| KR102693777B1 (ko) * | 2017-06-02 | 2024-08-08 | 화이자 인코포레이티드 | Flt3에 특이적인 항체 및 이의 용도 |
| CN119899277A (zh) * | 2017-06-02 | 2025-04-29 | 辉瑞公司 | 靶向flt3的嵌合抗原受体 |
| WO2019023097A1 (en) * | 2017-07-26 | 2019-01-31 | Smet Pharmaceutical Inc | ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE |
| EA202090387A1 (ru) * | 2017-07-31 | 2020-05-21 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и flt3 |
| JP2020533002A (ja) | 2017-09-13 | 2020-11-19 | ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | メラニン抗体及びその使用 |
| AU2018348093A1 (en) * | 2017-10-10 | 2020-05-28 | Sanofi | Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies |
| AU2018349093A1 (en) | 2017-10-12 | 2020-05-28 | Mcmaster University | T cell-antigen coupler with Y182T mutation and methods and uses thereof |
| BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
| US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| CN111655729B (zh) | 2017-12-19 | 2023-10-20 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
| AU2018393076B2 (en) | 2017-12-19 | 2025-11-20 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| WO2019126398A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Wnt surrogate molecules and uses thereof |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| JP2021512914A (ja) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法 |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| SG11202007945UA (en) | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JP7288913B2 (ja) | 2018-03-14 | 2023-06-08 | アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク | 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| AU2019271263A1 (en) * | 2018-05-16 | 2020-12-03 | Dragonfly Therapeutics, Inc. | Protein binding NKG2D, CD16 and a fibroblast activation protein |
| EP3796977A4 (en) * | 2018-05-17 | 2022-03-02 | The Board of Trustees of the Leland Stanford Junior University | RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| MX2020013443A (es) | 2018-06-13 | 2021-02-26 | Novartis Ag | Receptores de antigeno quimerico de bcma y usos de los mismos. |
| US12473360B2 (en) | 2018-06-14 | 2025-11-18 | Bioatla, Inc. | Multi-specific antibody constructs |
| WO2019243564A1 (en) | 2018-06-21 | 2019-12-26 | Technische Universitaet Muenchen | Hepatitis b and/or hepatitis d-permissive cells and animals |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN112689642B (zh) * | 2018-07-17 | 2025-01-17 | 特拉姆维拉免疫美国有限公司 | 具有各种不同的构建物优化的t细胞抗原偶联物 |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| MY205658A (en) * | 2018-09-11 | 2024-11-04 | Deutsches Krebsforschungszentrumstiftung Des Ffentlichen Rechts | Improved anti-flt₃ antigen binding proteins |
| EP3623383A1 (en) | 2018-09-11 | 2020-03-18 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved bispecific flt3xcd3 antigen binding proteins |
| WO2020102233A1 (en) * | 2018-11-13 | 2020-05-22 | Jn Biosciences Llc | Bispecific antibodies for activation of immune cells |
| MY198034A (en) * | 2018-12-21 | 2023-07-27 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
| WO2020132810A1 (en) * | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| CN114026122B (zh) | 2019-02-21 | 2024-12-31 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| US11912767B2 (en) | 2019-03-22 | 2024-02-27 | Regeneron Pharmaceuticals, Inc. | EGFR × CD28 multispecific antibodies |
| BR112021022135A2 (pt) * | 2019-05-06 | 2023-02-28 | Univ Brown | Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor |
| JOP20210297A1 (ar) | 2019-05-08 | 2023-01-30 | Janssen Biotech Inc | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية |
| MX2022004430A (es) * | 2019-10-15 | 2022-07-19 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). |
| EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| BR112022013633A2 (pt) * | 2020-01-09 | 2022-09-13 | Biomunex Pharmaceuticals | Anticorpos multiespecíficos que ligam tanto células mait quanto tumorais |
| CN113088495B (zh) * | 2020-01-09 | 2024-08-16 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN115605512A (zh) * | 2020-03-13 | 2023-01-13 | 詹森生物科技公司（Us） | 用于调节δ链介导的免疫的材料和方法 |
| US20240239912A1 (en) * | 2020-04-10 | 2024-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted reduction of activated immune cells |
| BR112022021884A2 (pt) | 2020-05-06 | 2022-12-20 | Dragonfly Therapeutics Inc | Proteínas que se ligam a nkg2d, cd16 e clec12a |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| IL297880A (en) * | 2020-06-23 | 2023-01-01 | Hoffmann La Roche | Agonistic cd28 antigen binding molecules targeting her2 |
| KR102607909B1 (ko) * | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| UY39488A (es) | 2020-10-28 | 2022-04-29 | Janssen Biotech Inc | Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma |
| AU2021368272A1 (en) * | 2020-11-02 | 2023-06-08 | Attralus, Inc. | Sap fc fusion proteins and methods of use |
| KR20230098317A (ko) | 2020-11-03 | 2023-07-03 | 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 | 표적 세포가 제한되는, 공동자극, 이중특이적 및 2가 항-cd28 항체 |
| KR20230148837A (ko) | 2021-02-25 | 2023-10-25 | 라이엘 이뮤노파마, 인크. | Ror1 표적화 키메라 항원 수용체 |
| WO2022180172A1 (en) | 2021-02-26 | 2022-09-01 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
| US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
| WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| EP4582106A1 (en) | 2022-08-29 | 2025-07-09 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2024170555A1 (en) | 2023-02-14 | 2024-08-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Il-15 fusion proteins with improved properties |
| EP4527851A1 (en) | 2023-09-22 | 2025-03-26 | Bayer Aktiengesellschaft | Bispecific antibodies binding ltbr and lrrc15 |
| WO2025147512A1 (en) * | 2024-01-02 | 2025-07-10 | Eli Lilly And Company | Immunogenicity assessment platform for biotherapeutic proteins |
| WO2025185760A1 (en) * | 2024-03-08 | 2025-09-12 | Itabmed Biopharmaceutical (Shanghai) Co., Ltd. | Multispecific antigen binding proteins and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809951D0 (en) * | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| EP1810980A1 (en) * | 2004-10-28 | 2007-07-25 | Osaka University | Interleukin-6 inhibitors |
| AU2006239851B2 (en) | 2005-04-26 | 2011-06-16 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| UA101142C2 (ru) * | 2006-03-17 | 2013-03-11 | Байоджэн Айдэк Ма Инк. | Способ разработки антитела |
| EA015992B1 (ru) * | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| KR20100058509A (ko) * | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| TWI464262B (zh) * | 2007-09-26 | 2014-12-11 | 中外製藥股份有限公司 | 抗體固定區的變異 |
| PL2310412T3 (pl) | 2008-06-20 | 2018-10-31 | Novartis Ag | Immunoglobuliny o zmniejszonej agregacji |
| EP2470568A2 (en) * | 2009-08-29 | 2012-07-04 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| JP2013507926A (ja) * | 2009-10-14 | 2013-03-07 | メリマック ファーマシューティカルズ インコーポレーティッド | ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用 |
| EP2516468B1 (en) * | 2009-12-23 | 2016-03-02 | Synimmune GmbH | Anti-flt3 antibodies and methods of using the same |
| CA2855864A1 (en) * | 2011-11-17 | 2013-05-23 | Gundram Jung | Bi-specific antibodies for treating b-cell mediated autoimmune diseases or auto-reactive b-cells |
| DK2794658T3 (en) * | 2011-12-19 | 2017-06-19 | Synimmune Gmbh | BISPECIFIC ANTIBODY MOLECULE |
| EP2985294A1 (en) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| EP3192810A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
-
2012
- 2012-11-12 DK DK12798623.0T patent/DK2794658T3/en active
- 2012-11-12 ES ES12798623.0T patent/ES2628075T3/es active Active
- 2012-11-12 EP EP12798623.0A patent/EP2794658B1/en active Active
- 2012-11-12 LT LTEP12798623.0T patent/LT2794658T/lt unknown
- 2012-11-12 CN CN201280070091.5A patent/CN104203981A/zh active Pending
- 2012-11-12 BR BR112014015018-4A patent/BR112014015018A2/pt not_active Application Discontinuation
- 2012-11-12 HR HRP20170658TT patent/HRP20170658T1/hr unknown
- 2012-11-12 US US14/366,669 patent/US9718893B2/en active Active
- 2012-11-12 CA CA2859767A patent/CA2859767C/en not_active Expired - Fee Related
- 2012-11-12 JP JP2014547791A patent/JP6441079B2/ja active Active
- 2012-11-12 WO PCT/EP2012/072364 patent/WO2013092001A1/en not_active Ceased
- 2012-11-12 SI SI201230939A patent/SI2794658T1/sl unknown
- 2012-11-12 HU HUE12798623A patent/HUE033245T2/hu unknown
- 2012-11-12 EA EA201400709A patent/EA201400709A1/ru unknown
-
2017
- 2017-06-27 US US15/634,990 patent/US20180057608A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9718893B2 (en) | 2017-08-01 |
| US20150119555A1 (en) | 2015-04-30 |
| EA201400709A1 (ru) | 2016-08-31 |
| LT2794658T (lt) | 2017-05-10 |
| BR112014015018A2 (pt) | 2020-10-27 |
| EP2794658B1 (en) | 2017-03-15 |
| EP2794658A1 (en) | 2014-10-29 |
| SI2794658T1 (sl) | 2017-05-31 |
| JP2015502373A (ja) | 2015-01-22 |
| CA2859767C (en) | 2018-09-11 |
| DK2794658T3 (en) | 2017-06-19 |
| JP6441079B2 (ja) | 2018-12-19 |
| HUE033245T2 (hu) | 2017-11-28 |
| HRP20170658T1 (hr) | 2017-06-30 |
| CN104203981A (zh) | 2014-12-10 |
| US20180057608A1 (en) | 2018-03-01 |
| CA2859767A1 (en) | 2013-06-27 |
| WO2013092001A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2628075T3 (es) | Molécula de anticuerpo biespecífica | |
| ES3008567T3 (en) | Recombinant antibody molecule and its use for target cell restricted t cell activation | |
| ES2255050T3 (es) | Vectores de expresion que codifican proteinas de fusion biespecificas biologicamente activas en celulas de mamiferos. | |
| RU2685479C2 (ru) | Химерный антигенный рецептор | |
| ES2720730T3 (es) | Diacuerpos Fc monovalentes biespecíficos que son capaces de unirse a CD32B y CD79b y usos de los mismos | |
| JP6893939B2 (ja) | Ｐｓｍａ結合抗体及びその使用 | |
| CN114616244A (zh) | 特异性结合mage-a的抗原结合蛋白 | |
| TW202019473A (zh) | 抗steap1抗原結合蛋白 | |
| BR112020015568A2 (pt) | Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer | |
| CN115667314A (zh) | T细胞双特异性结合蛋白 | |
| CN113056486B (zh) | 改善的抗flt3抗原结合蛋白 | |
| EP4378960A1 (en) | Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof | |
| EP4400518A1 (en) | Antigen-targeting, anti-cd16a and immune effector cell-activating trifunctional fusion protein, and use thereof | |
| KR102618373B1 (ko) | 키메라성 클로로톡신 수용체 | |
| EP4349870A1 (en) | Anti-cd3 antibody variant, fusion protein, and application | |
| RU2830982C2 (ru) | Улучшенные анти-flt3 антигенсвязывающие белки | |
| EA040607B1 (ru) | Молекула биспецифического антитела | |
| WO2025126216A1 (en) | Improved acetylcholine receptor molecules and use thereof | |
| WO2025247196A1 (zh) | 一种多功能融合多肽 | |
| BR112016020518B1 (pt) | Receptor antigênico quimérico |